No Pfizer COVID-19 Vaccine Expected Before Election
MONDAY, Oct. 19, 2020 -- Pfizer will not apply for emergency authorization of its COVID-19 vaccine before the third week in November, the company's chief executive said in a statement posted to the Pfizer website on Friday.
This is a reversal from the company's previous claims that it would apply for the approval in October, The New York Timesreported. Even though Pfizer could have preliminary data about the vaccine's effectiveness by the end of October, gathering safety and manufacturing data would take until at least the third week of November, chief executive Albert Bourla, M.D., said in the statement.
Pfizer's announcement was welcomed by some scientists. "This is good, really good," Eric Topol, M.D., a clinical trial expert at Scripps Research in San Diego, toldThe Times. He was one of 60 public health officials and other medical experts who sent a letter to Pfizer urging it not to rush its vaccine.
Pfizer is one of four companies with a COVID-19 vaccine in late-stage clinical trials in the United States. The others are Moderna, AstraZeneca, and Johnson & Johnson. Pfizer has given the most optimistic timeline, while the other three have said later this year is more likely.
© 2021 HealthDay. All rights reserved.
Posted: October 2020
Further Support and Information on COVID-19
Read this next
MONDAY, Jan. 25, 2021 -- Pfizer will provide fewer vials of its COVID-19 vaccine to the United States in the coming months after it was discovered that it had previously shipped...
MONDAY, Jan. 25, 2021 -- Moderna says its COVID-19 vaccine remains effective against two worrisome new coronavirus variants from Britain and South Africa, but it is somewhat less...
MONDAY, Jan. 25, 2021 -- Anthony Fauci, M.D., will receive the 2021 Public Welfare Medal for his "decades-long leadership in combating emerging infectious diseases, from the AIDS...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.